Hongsheng Gui1, Ruicong She2, Jasmine Luzum1,3, Jia Li2, Timothy D Bryson1, Yigal Pinto4, Hani N Sabbah5, L Keoki Williams1, David E Lanfear1,5. 1. Center for Individualized and Genomic Medicine Research (CIGMA) (H.G., J. Luzum, T.D.B., K.W., D.E.L.), Henry Ford Hospital. 2. Department of Public Health Sciences, Henry Ford Health System, Detroit (R.S., J. Li). 3. Department of Clinical Pharmacy, University of Michigan College of Pharmacy, Ann Arbor (J. Luzum). 4. Department of Cardiology, University of Amsterdam Medical Center, the Netherlands (Y.P.). 5. Heart and Vascular Institute (H.N.S., D.E.L.), Henry Ford Hospital.
Abstract
BACKGROUND: It remains unclear whether the plasma proteome adds value to established predictors in heart failure (HF) with reduced ejection fraction (HFrEF). We sought to derive and validate a plasma proteomic risk score (PRS) for survival in patients with HFrEF (HFrEF-PRS). METHODS: Patients meeting Framingham criteria for HF with EF<50% were enrolled (N=1017) and plasma underwent SOMAscan profiling (4453 targets). Patients were randomly divided 2:1 into derivation and validation cohorts. The HFrEF-PRS was derived using Cox regression of all-cause mortality adjusted for clinical score and NT-proBNP (N-terminal pro-B-type natriuretic peptide), then was tested in the validation cohort. Risk stratification improvement was evaluated by C statistic, integrated discrimination index, continuous net reclassification index, and median improvement in risk score for 1-year and 3-year mortality. RESULTS: Participants' mean age was 68 years, 48% identified as Black, 35% were female, and 296 deaths occurred. In derivation (n=681), 128 proteins associated with mortality, 8 comprising the optimized HFrEF-PRS. In validation (n=336) the HFrEF-PRS associated with mortality (hazard ratio, 2.27 [95% CI, 1.84-2.82], P=6.3×10-14), Kaplan-Meier curves differed significantly between HFrEF-PRS quartiles (P=2.2×10-6), and it remained significant after adjustment for clinical score and NT-proBNP (hazard ratio, 1.37 [95% CI, 1.05-1.79], P=0.021). The HFrEF-PRS improved metrics of risk stratification (C statistic change, 0.009, P=0.612; integrated discrimination index, 0.041, P=0.010; net reclassification index=0.391, P=0.078; median improvement in risk score=0.039, P=0.016) and associated with cardiovascular death and HF phenotypes (eg, 6-minute walk distance, EF change). Most HFrEF-PRS proteins had little known connection to HFrEF. CONCLUSIONS: A plasma multiprotein score improved risk stratification in patients with HFrEF and identified novel candidates.
BACKGROUND: It remains unclear whether the plasma proteome adds value to established predictors in heart failure (HF) with reduced ejection fraction (HFrEF). We sought to derive and validate a plasma proteomic risk score (PRS) for survival in patients with HFrEF (HFrEF-PRS). METHODS: Patients meeting Framingham criteria for HF with EF<50% were enrolled (N=1017) and plasma underwent SOMAscan profiling (4453 targets). Patients were randomly divided 2:1 into derivation and validation cohorts. The HFrEF-PRS was derived using Cox regression of all-cause mortality adjusted for clinical score and NT-proBNP (N-terminal pro-B-type natriuretic peptide), then was tested in the validation cohort. Risk stratification improvement was evaluated by C statistic, integrated discrimination index, continuous net reclassification index, and median improvement in risk score for 1-year and 3-year mortality. RESULTS: Participants' mean age was 68 years, 48% identified as Black, 35% were female, and 296 deaths occurred. In derivation (n=681), 128 proteins associated with mortality, 8 comprising the optimized HFrEF-PRS. In validation (n=336) the HFrEF-PRS associated with mortality (hazard ratio, 2.27 [95% CI, 1.84-2.82], P=6.3×10-14), Kaplan-Meier curves differed significantly between HFrEF-PRS quartiles (P=2.2×10-6), and it remained significant after adjustment for clinical score and NT-proBNP (hazard ratio, 1.37 [95% CI, 1.05-1.79], P=0.021). The HFrEF-PRS improved metrics of risk stratification (C statistic change, 0.009, P=0.612; integrated discrimination index, 0.041, P=0.010; net reclassification index=0.391, P=0.078; median improvement in risk score=0.039, P=0.016) and associated with cardiovascular death and HF phenotypes (eg, 6-minute walk distance, EF change). Most HFrEF-PRS proteins had little known connection to HFrEF. CONCLUSIONS: A plasma multiprotein score improved risk stratification in patients with HFrEF and identified novel candidates.
Authors: Adrienne Tin; Bing Yu; Jianzhong Ma; Kunihiro Masushita; Natalie Daya; Ron C Hoogeveen; Christie M Ballantyne; David Couper; Casey M Rebholz; Morgan E Grams; Alvaro Alonso; Thomas Mosley; Gerardo Heiss; Peter Ganz; Elizabeth Selvin; Eric Boerwinkle; Josef Coresh Journal: J Appl Lab Med Date: 2019-01-22
Authors: Thomas J Wang; Martin G Larson; Daniel Levy; Emelia J Benjamin; Eric P Leip; Torbjorn Omland; Philip A Wolf; Ramachandran S Vasan Journal: N Engl J Med Date: 2004-02-12 Impact factor: 91.245
Authors: John C Rohloff; Amy D Gelinas; Thale C Jarvis; Urs A Ochsner; Daniel J Schneider; Larry Gold; Nebojsa Janjic Journal: Mol Ther Nucleic Acids Date: 2014-10-07 Impact factor: 10.183
Authors: Jasmine A Luzum; Edward Peterson; Jia Li; Ruicong She; Hongsheng Gui; Bin Liu; John A Spertus; Yigal M Pinto; L Keoki Williams; Hani N Sabbah; David E Lanfear Journal: J Am Heart Assoc Date: 2018-05-08 Impact factor: 5.501
Authors: Ali Javaheri; Ahmed Diab; Lei Zhao; Chenao Qian; Jordana B Cohen; Payman Zamani; Anupam Kumar; Zhaoqing Wang; Christina Ebert; Joseph Maranville; Erika Kvikstad; Michael Basso; Vanessa van Empel; A Mark Richards; Robert N Doughty; Ernst Rietzschel; Karl Kammerhoff; Joseph Gogain; Peter Schafer; Dietmar A Seiffert; David A Gordon; Francisco Ramirez-Valle; Douglas L Mann; Thomas P Cappola; Julio A Chirinos Journal: Circ Heart Fail Date: 2022-08-09 Impact factor: 10.447
Authors: Nicolas Girerd; John Cleland; Stefan D Anker; William Byra; Carolyn S P Lam; David Lapolice; Mandeep R Mehra; Dirk J van Veldhuisen; Emmanuel Bresso; Zohra Lamiral; Barry Greenberg; Faiez Zannad Journal: Sci Rep Date: 2022-05-20 Impact factor: 4.996